A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.

Phase 2

Kinevant Sciences GmbH

Antibodies, Monoclonal